Novartis Terminates Study in Type 2 Diabetes Patients

Novartis has decided to terminate the ALTITUDE study evaluating the potential benefits of Rasilez/Tekturna (aliskiren) in reduction of risk of cardiovascular and renal events in patients with type 2 diabetes and renal impairment… Read more

Novartis Receives Positive Opinion on New Diabetic Macular Edema Drug

Novartis has announced that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Lucentis (ranibizumab) for the treatment of patients with visual impairment due to diabetic macular edema (DME).
The submission was supported by data from two Novartis-funded clinical trials, RESTORE and RESOLVE, which showed that Lucentis… Read more

Novartis’ Ranibizumab More Effective Than Laser Treatment in Treating Vision Loss due to Diabetic Macular Edema

Novartis announced that first results of the RESTORE Phase III study show that ranibizumab is significantly more effective than laser treatment, the current standard of care, at treating visual impairment due to diabetic macular edema (DME), a serious complication of diabetes. The one year results show that 37% of patients treated with ranibizumab 0.5 mg alone, and 43% of those treated with ranibizumab… Read more

Senator Asks Drug Companies to Explain High Prices

Senator Herb Kohl (D), chair of the Special Committee on Aging, sent letters to AstraZeneca, GlaxoSmithKline, Eli Lilly, Novartis, Pfizer, and Sanofi-Aventis asking them to explain why Americans on average pay twice as much as people in other industrialized countries for prescription drugs… Read more

Subscribe to our Newsletter

Hide me